Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Analysts at Oppenheimer raised their FY2018 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, October 17th, Zacks Investment Research reports. Oppenheimer analyst E. Rajavelu now anticipates that the company will earn $2.66 per share for the year, up from their prior forecast of $2.64. Oppenheimer has a “Hold” rating on the stock.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.00 earnings per share.
TEVA traded down $0.39 during midday trading on Thursday, hitting $23.45. The stock had a trading volume of 6,637,061 shares, compared to its average volume of 10,918,274. The firm has a market cap of $24.13 billion, a P/E ratio of 7.39, a P/E/G ratio of 7.28 and a beta of 0.77. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 1 year low of $11.44 and a 1 year high of $25.96.
Institutional investors and hedge funds have recently bought and sold shares of the business. First Republic Investment Management Inc. raised its holdings in Teva Pharmaceutical Industries by 30.1% in the second quarter. First Republic Investment Management Inc. now owns 20,110 shares of the company’s stock worth $489,000 after purchasing an additional 4,657 shares in the last quarter. Global Financial Private Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 92.2% during the second quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock valued at $575,000 after acquiring an additional 11,335 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% during the second quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock valued at $3,946,000 after acquiring an additional 34,305 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 553.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock valued at $544,000 after acquiring an additional 18,938 shares in the last quarter. Finally, Toronto Dominion Bank bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $669,000. Institutional investors and hedge funds own 65.10% of the company’s stock.
In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now owns 2,376 shares in the company, valued at $56,334.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,531 shares of company stock valued at $152,749. 0.43% of the stock is owned by corporate insiders.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.